HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
23 Dicembre 2024 - 2:31PM
Business Wire
- HeartBeam system was recently cleared by US Food and Drug
Administration (FDA) for comprehensive arrhythmia assessment
- The Company is gearing up for an Early Access Program to gain
initial commercialization learnings
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology
company focused on transforming cardiac care by providing powerful
cardiac insights, today announced that it will attend the JP Morgan
2025 Annual Healthcare Conference taking place January 13-16, 2025
at the Westin St. Francis Hotel in San Francisco, CA.
HeartBeam Chief Executive Officer, Robert Eno, and Chief
Financial Officer, Timothy Cruickshank, will be available January
13-15 for off-site meetings with investors and potential
commercialization and co-development partners to discuss the
Company’s recently announced US Food and Drug Administration (FDA)
510(k) clearance of the HeartBeam system for comprehensive
arrhythmia assessment. With its patented design, the HeartBeam
device is the first-of-its-kind to receive FDA clearance. As a
high-fidelity electrocardiogram (ECG) system with a credit
card-sized form factor and cable-free design, it captures heart
signals from three distinct directions for actionable heart health
information.
HeartBeam's proprietary technology has the potential to unlock
valuable diagnostic and predictive insights. The ease of collecting
higher-fidelity ECG signals will enable patients to gather a series
of recordings over time. The Company aims to leverage AI to analyze
this rich set of data, delivering a longitudinal view of a
patient’s cardiac health and predicting cardiac conditions before
symptoms appear. HeartBeam believes its groundbreaking technology
presents a transformative opportunity to bring about a paradigm
shift in cardiovascular care for millions of patients globally.
To schedule an off-site one-on-one meeting with HeartBeam
management during the event, please contact MZ Group at
BEAT@mzgroup.us.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
dedicated to transforming the detection and monitoring of critical
cardiac conditions. The Company is creating the first ever
cable-free synthesized 12-lead ECG capable of capturing the heart’s
electrical signals from three distinct directions. This platform
technology is designed for portable devices that can be used
wherever the patient is to deliver actionable heart intelligence.
Physicians will be able to identify cardiac health trends and acute
conditions and direct patients to the appropriate care – all
outside of a medical facility, thus redefining the future of
cardiac health management. The Company holds 13 US and 4
international issued patents related to technology enablement. For
additional information, visit HeartBeam.com.
About the HeartBeam System
The HeartBeam System is a portable non-invasive recorder
intended to record, store, and transfer a patient’s 3-Lead (in
three-directions) electrocardiogram (ECG) acquired from 5
electrodes. The device is intended to be used by adult patients in
either a clinical setting or at home. The device does not conduct
cardiac analysis and can be used with an ECG Viewer software system
for manual interpretation of non-life-threatening arrhythmias by a
physician or healthcare professional. For full safety information,
see the full Instructions for Use or Clinician Portal Manual.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241222771475/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:media@heartbeam.com
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Dic 2023 a Dic 2024